Adakveo® (crizanlizumab-tmca)
for Sickle Cell DIsease
Adakveo (crizanlizumab-tmca) is used in people aged 16 and older with sickle cell disease to reduce the frequency of painful episodes (crises) caused by the disease. It works by attaching to P-selectin, a substance in the body, and preventing blood cells from sticking together. Crizanlizumab belongs to a class of medications known as monoclonal antibodies, helping to manage sickle cell disease and reduce the occurrence of painful crises.
